Semaglutide vs Tirzepatide: Which Produces More Weight Loss?

Both semaglutide and tirzepatide are GLP-1 receptor agonists that produce significant weight loss. The head-to-head question — which works better — was finally answered by the SURMOUNT-5 trial in late 2024. Here's everything you need to know.

The Clinical Trial Data

Semaglutide (STEP Trials)

The STEP clinical trials enrolled over 4,500 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Key results at maximum dose (2.4 mg/week):

• Average weight loss: 14.9% of body weight over 68 weeks
• Two-thirds of participants lost ≥10% of body weight
• One-third lost ≥20%
• STEP 4 showed weight regain after stopping — most weight returns within 1 year

Tirzepatide (SURMOUNT Trials)

The SURMOUNT trials enrolled a similar population. Results at maximum dose (15 mg/week):

• Average weight loss: 20.9% of body weight over 72 weeks (SURMOUNT-1)
• In the highest-dose group: 22.5% average
• 57% of participants lost ≥20% of body weight
• SURMOUNT-2 (diabetes patients): 15.7% average

Head-to-Head: SURMOUNT-5 (2024)

The first direct comparison trial. Tirzepatide (10–15 mg/week) vs semaglutide (1.7–2.4 mg/week) over 72 weeks:

• Tirzepatide: 20.2% average weight loss
• Semaglutide: 13.7% average weight loss
• Tirzepatide produced ~47% more weight loss than semaglutide at comparable doses

Why Does Tirzepatide Produce More Weight Loss?

Tirzepatide is a dual agonist — it activates both GLP-1 receptors (same as semaglutide) AND GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) appears to add appetite suppression through mechanisms separate from GLP-1. The dual activation produces a synergistic effect that exceeds what either receptor pathway achieves alone.

Side Effect Comparison

Both medications share the same GI side effect profile: nausea, diarrhea, vomiting, constipation, and reduced appetite. These are most prominent during titration and improve substantially at maintenance doses.

Some real-world reports suggest tirzepatide may have slightly better GI tolerability than semaglutide at equivalent weight-loss doses, possibly due to the GIP component moderating some of the GLP-1-mediated GI effects. Clinical trial comparison is difficult because the trials weren't designed for head-to-head tolerability assessment.

Cardiovascular Data

Semaglutide has the SELECT trial (2023) showing a 20% reduction in major adverse cardiovascular events (MACE) in patients with existing cardiovascular disease. This is a significant advantage — the first weight-loss medication to show cardiovascular mortality reduction.

Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) results were pending as of early 2026. If SURPASS-CVOT shows similar CV benefits, tirzepatide's advantage over semaglutide becomes more complete.

Who Should Consider Each

Consider semaglutide if:

• You have existing cardiovascular disease (strongest CV evidence)
• You're already on semaglutide with good results and tolerability
• You prefer the option with more long-term real-world data
• Cost or insurance coverage favors semaglutide in your situation

Consider tirzepatide if:

• Maximum weight loss is the primary goal
• You haven't started a GLP-1 yet
• You previously tried semaglutide with insufficient response
• You have significant insulin resistance or pre-diabetes (GIP component helps)

Dosing and Titration

Both require careful titration to minimize GI side effects. Use our GLP-1 Titration Tracker to generate a personalized week-by-week injection schedule.